[Chimeric antigen receptors in oncology: clinical applications and new developments]
Related Experiment Video
Updated: Dec 6, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Alexander Michels1, Jessica Hartmann1, Christian J Buchholz2
1Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland.
Abstract:
In 2018, two novel cancer therapies based on chimeric antigen receptors (CARs) were granted marketing authorization in the European Union. Authorized for use against advanced lymphoma and/or leukemia, the products were at the center of international attention, not only due to their novel mode of action and their encouraging efficacy but also because of their sometimes severe side effects and the economic and logistic challenges posed by their manufacture. Now, almost two years later, hundreds of active clinical trials emphasize the global drive to harness the full potential of CAR technology.In this article, we describe the mode of action of CAR T and CAR NK cells and review the clinical testing situation as well as early real-world data. In recent years, preclinical studies using advanced animal models have provided first insights into the mechanisms underlying the severe side effects of CAR T therapy. We summarize their results and describe the available models. Additionally, we discuss potential solutions to the hurdles currently limiting CAR technology. So far used as last-line treatment for patients with aggressive disease, CAR technology has the potential to become a new, broadly effective standard for tumor therapy.
Insights
Chimeric antigen receptor (CAR) T and NK cell therapies show promise for advanced cancers like lymphoma and leukemia. Ongoing research aims to overcome side effects and manufacturing challenges for broader application.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Two novel chimeric antigen receptor (CAR) T-cell therapies received EU marketing authorization in 2018 for advanced lymphoma and leukemia.
- These groundbreaking treatments garnered significant attention due to their innovative mechanisms, efficacy, severe side effects, and manufacturing complexities.
Purpose of the Study:
- To describe the mode of action for CAR T and CAR NK cells.
- To review the current clinical trial landscape and early real-world data for CAR therapies.
- To summarize preclinical findings on CAR T-cell therapy side effects and discuss potential solutions to current limitations.
Main Methods:
- Review of clinical trial data and real-world evidence for CAR T and CAR NK cell therapies.
- Analysis of preclinical studies investigating the mechanisms of CAR T-cell therapy side effects.
- Discussion of challenges and potential solutions in CAR technology development and application.
Main Results:
- Hundreds of active clinical trials worldwide highlight the rapid advancement and global interest in CAR technology.
- Preclinical models are beginning to elucidate the mechanisms behind severe side effects associated with CAR T-cell therapy.
- Early real-world data and ongoing clinical trials are crucial for understanding the therapeutic potential and limitations of CAR technology.
Conclusions:
- CAR T and CAR NK cell therapies represent a significant advancement in cancer treatment, particularly for aggressive hematological malignancies.
- Addressing side effects and manufacturing hurdles is critical for expanding the use of CAR technology.
- CAR technology holds the potential to evolve from last-line treatment to a broadly effective standard of care for various tumor types.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019